TY  - JOUR 
AU  - Martínez-Cuadrón, David
AU  - Montesinos, Pau
AU  - Vellenga, Edo
AU  - Bernal, Teresa
AU  - Salamero, Olga
AU  - Holowiecka, Aleksandra
AU  - Brunet, Salut
AU  - Gil, Cristina
AU  - Benavente, Celina
AU  - Ribera, Josep Maria
AU  - Pérez Encinas, Manuel Mateo
AU  - de la Serna, Javier
AU  - Esteve, Jordi
AU  - Rubio, Vicente
AU  - González-Campos, José
AU  - Escoda, Lourdes
AU  - Amutio, María Elena
AU  - Arnan, M.
AU  - Arias Sampedro, Jesús
AU  - Negri, S.
AU  - Lowenberg, Bob
AU  - Sanz, Miguel A.
PY  - 2018
UR  - http://hdl.handle.net/20.500.11940/22461
AB  - [EN] Treatment outcome in older patients with acute promyelocytic leukemia (APL) is lower compared with younger patients, mainly because of a higher induction death rate and postremission non-relapse mortality (NRM). This prompted us to design a risk-...
LA  - eng
KW  - Disease-Free Survival
KW  - Recurrence
KW  - Aged
KW  - Risk Factors
KW  - Anthracyclines
KW  - Treatment Outcome
KW  - Remission Induction
KW  - Leukemia, Promyelocytic, Acute
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Tretinoin
TI  - Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy
DO  - 10.1038/leu.2017.178
T2  - Leukemia
M2  - 21
KW  - ATRA
KW  - CHUS
KW  - CHULA
VL  - 32
ER  -